CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Pipeline Review, H1 2016

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Pipeline Review, H1 2016
Published Jun 22, 2016
65 pages — Published Jun 22, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Pipeline Review, H1 2016, provides in depth analysis on CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted pipeline therapeutics.

The report provides comprehensive information on the CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG)
- The report reviews CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics and enlists all their major and minor projects
- The report assesses CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued p

  
Source:
Document ID
GMDHC0054TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents25
  List of Tables61
  List of Figures61
Introduction71
  Global Markets Direct Report Coverage71
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) Overview81
Therapeutics Development94
  CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) Products under Development by Stage of Development91
  CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) Products under Development by Therapy Area101
  CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) Products under Development by Indication112
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) Pipeline Products Glance132
  Late Stage Products131
  Early Stage Products141
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) Products under Development by Companies153
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) Products under Development by Universities/Institutes182
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) Therapeutics Assessment207
  Assessment by Monotherapy/Combination Products201
  Assessment by Mechanism of Action212
  Assessment by Route of Administration232
  Assessment by Molecule Type252
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) Companies Involved in Therapeutics Development278
  Biogen, Inc.271
  Bristol-Myers Squibb Company281
  eTheRNA Immunotherapies NV291
  ImmuNext, Inc.301
  Juno Therapeutics Inc.311
  MedImmune, LLC321
  Targovax AS331
  XL-protein GmbH341
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) Drug Profiles3521
  Antibodies to Antagonize CD40L for Autoimmune Diseases and GVHD Drug Profile351
  Antibody to Target CD40 Ligand for Immunology Drug Profile361
  BIIB-063 Drug Profile371
  BMS-986004 Drug Profile381
  Cellular Immunotherapy to Activate CD40L and to Target CD19 for B-Cell Malignancies Drug Profile392
  FFP-102 Drug Profile411
  hepatitis B vaccine Drug Profile421
  ISF-35 Drug Profile432
  LOAd-700 Drug Profile451
  MEDI-4920 Drug Profile461
  MegaCD40L Drug Profile471
  Oligonucleotide to Activate CD40L, CD70 and TLR-4 for Oncology and Infectious Diseases Drug Profile481
  ONCOS-402 Drug Profile491
  TDI-28 Drug Profile501
  TDI-846 Drug Profile511
  UltraCD40L Drug Profile521
  Vaccine to Target CD40L and GM-CSF for Oncology Drug Profile532
  XL-050 Drug Profile551
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) Dormant Projects562
CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) Featured News &Press Releases586
  Nov 17, 2015: Memgen Announces Preclinical Results for ISF35 in Combination with Checkpoint Inhibitors in a Model of Metastatic Melanoma581
  Dec 07, 2011: Memgen Announces Upcoming Presentation For ISF35 In Chronic Lymphocytic Leukemia At 2011 ASH Annual Meeting581
  Jun 21, 2011: Memgen Presents Clinical Results For ISF35 In Chronic Lymphocytic Leukemia At ASCO 2011591
  Dec 09, 2010: Memgen Announces Clinical And Preclinical Results For ISF35 In Chronic Lymphocytic Leukemia And Non-Hodgkin's Lymphoma591
  Dec 08, 2009: Memgen Announces Positive Data Results Of ISF35 For Chronic Lymphocytic Leukemia601
  Dec 08, 2009: Memgen's ISF35 Sensitizes Cancer Cells To Chemotherapy611
  Dec 02, 2009: Memgen Selects Clinical Trial Results Of ISF35 For An Oral Presentation At ASH 2009 Annual Meeting611
  Dec 01, 2009: Memgen's Clinical Trial Results Of ISF35 For Chronic Lymphocytic Leukemia Selected For Presentation At ASH 2009 Annual Meeting621
  Jun 08, 2009: Memgen Reports Positive Results For ISF35 In High-Risk Chronic Lymphocytic Leukemia621
  Jun 04, 2009: Memgen Reports Positive Results For ISF35 In High-Risk Chronic Lymphocytic Leukemia622
Appendix642
  Methodology641
  Coverage641
  Secondary Research641
  Primary Research641
  Expert Panel Validation641
  Contact Us641
  Disclaimer651

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Pipeline Review, H1 2016" Jun 22, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/CD40-Ligand-T-Cell-Antigen-Gp39-or-TNF-Related-Activation-Protein-or-Tumor-Necrosis-Factor-Ligand-Superfamily-Member-5-or-CD154-or-CD40LG-Pipeline-Review-H1-2016-2088-15991>
  
APA:
Global Markets Direct - Market Research. (2016). CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Pipeline Review, H1 2016 Jun 22, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/CD40-Ligand-T-Cell-Antigen-Gp39-or-TNF-Related-Activation-Protein-or-Tumor-Necrosis-Factor-Ligand-Superfamily-Member-5-or-CD154-or-CD40LG-Pipeline-Review-H1-2016-2088-15991>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.